Gastroenterology, Hepatology & Digestive Disorders
Open AccessPrevalence of Liver Fibrosis Assessed by Transient Elastography in Patients with Type 2 Diabetes and MASLD at the Brazzaville University Hospital
Authors: Pérès Mardochée Motoula Latou, Rudel Godrèche Kondo, Clausina Mikolele Ahoui Apendi, Farel Elilie Mawa Ongoth, Rody Stéphane NGAMI, Ngala Akoa Itoua Ngaporo, Moria Gilga IBOBI, Bienvenu Hostaud Atipo Ibara, Marlyse Ngalessami Mouakosso, Bénédicte Ahombo Niotsebe, Sandra Céline ADOUA, Jile Florent Mimiesse Mounamou, Arnaud Mongo Onkouo, Blaise Irénée Atipo Ibara.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, with type 2 diabetes being one of majors risk factors for its progression to fibrosis. Understanding the prevalence of hepatic fibrosis in these patients living in Brazzaville is essential.
Aim: To assess the prevalence of hepatic fibrosis in patients with type 2 diabetes and MASLD.
Methods: We included 120 patients with type 2 diabetes and ultrasound confirmed hepatic steatosis. Transient elastography (Fibroscan) was used to evaluate hepatic fibrosis and its stage, with an elasticity > 7kPa indicating the presence of fibrosis. We analyzed the prevalence of fibrosis and identified associated factors.
Results: The median age was 56 years, with 77.5% of patients aged 50 or older, and 62.5% were female. Hepatic fibrosis was found in 43.3% of patients, with 14.2% presenting severe fibrosis. Severe hapatic steatosis was observed in 41.6% of participants. Factors associated with fibrosis included metabolic syndrome, dyslipidemia, insulin treatment and chronic kidney disease.
Conclusion: Hepatic fibrosis detected via elastography is common in type 2 diabetes patients with hepatic steatosis, highlighting the importance of its screening in routine clinical follow-up
Editor-in-Chief
View full editorial board →